ARR-217 (MRG007) — Interim data
H2 2026
Plan to complete Phase 1 dose escalation and enter into dose optimization for ARR-217, a CDH17 targeting ADC program, in the second half of 2026.Source filing
AVBP biotech catalysts & pipeline
ARRIVENT BIOPHARMA INC · Data as of 2026-09-08
Upcoming catalysts
firmonertinib — Topline data
2H 2026
Top-line data from the global pivotal FURVENT Phase 3 (NCT05607550) study for first-line EGFR exon 20 insertion mutant NSCLC is anticipated in 2H 2026.Source filing